This study examined the use of anti-tumor necrosis factor (anti-TNF)
from a US commercial health plan with claims for anti-TNFs (2006-2010) were defined as either biologic-naive or -exposed anti-TNF initiators based on previous nbDMARD use. Adherence to nbDMARDs and anti-TNF persistence were estimated. Cox regression estimated the association between nbDMARD adherence and anti-TNF persistence.
Results: Among 9764 patients identified (mean age 50.2 years; 78% female), 55% of biologic-naive patients and 49% of previously exposed patients initiated any combination therapy during follow-up. Among biologic-naive combination therapy patients, 53% adhered to nbDMARD therapy \80% of the time while receiving anti-TNF therapies; 33% had \60% adherence. Compared with the most adherent patients, patients adherent to nbDMARDs 20% to 79% of the time were 30% to 20% more likely to discontinue their anti-TNF therapy in the period [90 days after starting the anti-TNF therapy. This relationship was not observed for patients with nbDMARD adherence of \20% (who were less likely to discontinue their anti-TNF therapy during the first 90 days of treatment). Conclusion: Almost one-third of patients with RA receiving anti-TNF therapy received it as pure monotherapy. About one-third of combination therapy recipients had \60% adherence to nbDMARDs. Higher nbDMARD adherence may be associated with better Electronic supplementary material The online version of this article (doi:10.1007/s40744-015-0015-x) contains supplementary material, which is available to authorized users.
INTRODUCTION
Rheumatoid arthritis (RA) affects upwards of an estimated 1. 3 
million persons in the United
States over the age of 18 years, with a growing prevalence among those over the age of 60 [1, 2] . The clinical and economic burden of RA is significant [3] , whether measured by the impact on quality of life, direct treatment costs, or indirect costs in the form of productivity loss [4, 5] . Successful treatment of RA can improve patients' quality of life [5] and reduce costs associated with loss of productivity [6] .
Guidelines provided by the American College of Rheumatology call for early, aggressive treatment of RA to slow the progression of the disease [7] . Typically, non-biologic disease-modifying anti-rheumatic drugs (nbDMARDs) are the first line of treatment.
Biologics, including anti-tumor necrosis factor drugs (anti-TNFs), are often added to the nbDMARD for patients who do not experience improvement after nbDMARD treatment.
Studies have shown a better response to anti-TNFs when used in combination with nbDMARDs than when used as monotherapies [8, 9] . Adherence to nbDMARDs prescribed in combination with anti-TNFs may impact the benefit obtained with the use of these biologic therapies. The objectives of this study were to examine (1) the use of anti-TNF therapies as monotherapy, (2) adherence with concomitant nbDMARDs in patients receiving a combination of anti-TNFs and nbDMARDs, and (3) the impact of concomitant nbDMARD adherence on anti-TNF persistence in a real-world setting among commercially insured patients with RA.
METHODS

Study Design
A retrospective claims-based analysis using data from a US managed care plan was conducted.
Patients were followed from anti-TNF initiation to discontinuation of that specific anti-TNF or disenrollment from the managed care plan.
Data Sources
Patients were identified from a large US Patients with more than one biologic on a particular index date or with evidence of prior use of the index medication were excluded from analysis of that medication.
Also excluded were patients with conditions other than RA that were labeled indications for the biologic medications.
Study Measures
Patients were classified into several defined groups based on their treatment patterns with nbDMARD and anti-TNF medications, resulting in 3 main classifications. The first designation was based on prior biologic exposure.
'Biologic-exposed' patients were those who had filled a different biologic prescription during the 6-month baseline period prior to the index date, whereas 'biologic-naive' patients were those who did not.
The second classification placed patients into either combination therapy or monotherapy groups. 'Combination therapy initiators' were those who had filled prescriptions or administrations for nbDMARDs within 30 days after their index date, or who had filled a prescription within 30 days prior to the index date with a medication supply that covered the period through at least 30 days after the index date. 'Monotherapy initiators' were patients who initiated anti-TNF therapy and who did not meet the definition for combination therapy initiators. Third, we assessed what proportion of patients stayed on monotherapy for the entire duration of their anti-TNF treatment. 'Pure monotherapy' referred to treatment with anti-TNF monotherapy that never included an nbDMARD during anti-TNF follow-up, whereas patients with nbDMARD therapy at any time during anti-TNF follow-up were referred to as the 'any combination therapy' group.
The primary study outcomes included adherence with nbDMARDs and persistence with anti-TNF medications. Adherence to nbDMARDs was estimated from the proportion of days covered. Specifically, it represents the percentage of days that patients received any nbDMARD while they were receiving the anti-TNF therapy. Perfect (100%) adherence indicates that patients possessed some nbDMARD 100% of the time during their anti-TNF follow-up based on filled prescriptions or administrations. In addition to adherence with any nbDMARDs, adherence to MTX was assessed separately. Anti-TNF persistence represented the time from the start of use until discontinuation of that anti-TNF therapy (a gap in supply of 60 days or a switch to a different biologic) or censoring due to disenrollment or the end of the study. For medications identified in pharmacy claims, the last date of supply was identified based on the days' supply on all fills for that medication; for medications administered in a physician office or inpatient setting, the days' supply was imputed for the last administration based on dosing intervals described on medication labels. Patient characteristics included age, sex, and geographic location. Clinical characteristics were established during the 6-month baseline period before the index date.
Statistical Analysis
All study variables, including baseline and outcome measures, were analyzed descriptively. Numbers and percentages were calculated for dichotomous and polychotomous variables. Means, standard deviations, and percentiles were calculated for continuous variables. Descriptive analyses are presented separately for biologic-naive and previously exposed patients for each index anti-TNF. When comparing groups, the appropriate statistical test (e.g., t test, Mann-Whitney 
RESULTS
Sample Selection and Baseline
Characteristics After applying all of the inclusion and exclusion criteria, the final study population included a total of 9764 patients, with 7074 patients classified as biologic naive and 2690 classified as previously biologic exposed (Fig. 1) . The mean age of the study population was *50 years and study patients were predominately female (Table 1 ). More than half of all patients were located geographically in the South. Corticosteroids were used by 62% of patients with first-line monotherapy and 70% of patients with first-line combination therapy, although the proportion of days covered was low (17% and 22% of days for monotherapy and combination therapy, respectively).
Outcomes
Monotherapy Initiators vs. Combination
Therapy Initiators Among all patients initiating anti-TNFs, 45% of biologic-naive patients and 51% of biologic-exposed patients initiated an anti-TNF agent as a monotherapy; the remaining patients initiated anti-TNFs as part of combination therapy (Fig. 2 ). This was similar among the individual anti-TNF agents: 31% to 52% of biologic-naive patients and 46% to 55% of biologic-exposed patients were monotherapy initiators.
Pure Monotherapy vs. Any Combination
Therapy Users During anti-TNF follow-up, 27% of all patients in the biologic-naive group and 31% of all patients in the biologic-exposed group received anti-TNF therapy as pure monotherapy; the remaining patients received an nbDMARD during follow-up (Fig. 2) . When stratified by the individual anti-TNF agents, the percentage of patients identified as pure monotherapy ranged from 18% to 32% for the biologic-naive group and 23% to 35% for those previously exposed to biologics. 42% of biologic-naive patients on pure monotherapy and 89% of biologic-naive patients on combination therapy were administered an nbDMARD during the 6-month baseline period prior to initiating anti-TNF medication ( Table 1) ; for patients previously exposed to biologics, those values were 32% and 89%, respectively.
Adherence to nbDMARDs Among Any
Combination
Therapy Users Among biologic-naive combination therapy patients, 53% of patients adhered to nbDMARD therapy \80% of the time while receiving anti-TNFs (proportion of days covered \80%); 33% of the Fig. 1 Patient selection. For each qualifying line subsequent to the first line, patients can appear multiple times in this data set (i.e., multiple records per patient). ABT abatacept, anti-TNFs anti-tumor necrosis factor drugs, IFX infliximab, RTX rituximab, TOC tocilizumab patients had \60% adherence (Fig. 3a) . Among biologic-naive patients who received anti-TNF combination therapy with MTX, 58% had \80% adherence to MTX and 35% had \60% adherence to MTX while receiving the anti-TNF ( Fig. 3b) . Similar results were observed for anti-TNF patients previously exposed to biologics ( Fig. 3c, d) .
Association Between Concomitant nbDMARD Adherence and Anti-TNF Persistence Average persistence with anti-TNF treatment was lower for patients receiving pure monotherapy (333 days for biologic-naive and 283 days for previously exposed patients) than for combination therapy users (522 days for biologic-naive and 426 days for previously exposed patients). Overall, we did not find a significant association between adherence to concomitant nbDMARDs and anti-TNF persistence. It is known that while some biologic users may not respond right from the outset (primary non-response), a proportion of patients may fail to maintain their initial response (secondary non-response). We therefore examined the association within subgroups stratified by duration of follow-up (B90 days and [90 days) to determine whether nbDMARD adherence would have an impact within those time frames on primary or secondary non-response, respectively ( Fig. 4) 
DISCUSSION
Previous research has demonstrated enhanced efficacy of the anti-TNF therapies infliximab, etanercept, adalimumab, and golimumab when used in combination with MTX, compared with using these therapies as monotherapy [10] [11] [12] [13] [14] [15] . We examined the prevalence of anti-TNF monotherapy in a real-world setting and found that about one-third of patients with RA receiving anti-TNF therapy received it as pure monotherapy, which is consistent with previously published data [16, 17] . Furthermore, even among patients in our study cohort receiving combination therapy (anti-TNF ? nbDMARD), one-third had an nbDMARD adherence rate of \60%, suggesting that a substantial proportion of this patient population might not be receiving the full benefit offered by using the anti-TNF medications with concomitant nbDMARDs. Previous estimates of DMARD adherence vary substantially across studies. In a recent reviews of the literature [18, 19] , the authors found reported adherence rates that ranged from 22% to 107%, although there were a variety of study methods and definitions employed in the consistently non-adherent [20] , whereas in a more recent study that number was just over 10% [21] . Despite these difficulties, a recent prospective study that utilized electronic monitoring of medications (a method thought to provide some of the most accurate estimates of adherence) reported that 21% of patients with RA had an average adherence to DMARDs of C80% [22] , which is noticeably lower than the 41% to 47% of patients found in our study.
The reasons for non-adherence with nbDMARDs may be varied. For MTX, non-adherence has been shown to be associated with longer disease duration and low or moderate disease activity [23] .
Furthermore, while serious side effects of MTX are rare [24] , patient concerns regarding potential adverse effects of RA medication may influence their adherence [25] . A full understanding of the factors associated with adherence in patients with RA continues to be elusive [18] ; however, our data do not allow for further investigation as to the reasons for non-adherence. One possibility is that patients use corticosteroids as a replacement for combination therapy or to compensate for low adherence. However, in our study, the proportion of time that patients used corticosteroids was low (17-22% of days), suggesting that corticosteroids may have been used for flare-ups or to treat other conditions. Persistence is measured as the time from initiation of therapy to discontinuation of therapy, which could be a proxy for clinical effectiveness, tolerability, and patient/provider preferences. Several studies have demonstrated better persistence of anti-TNFs when combined Fig. 3 a Non-biologic disease-modifying anti-rheumatic drug and b methotrexate adherence in patients receiving any combination with nbDMARDs [8, 16, 17, [26] [27] [28] [29] , but the impact of adherence with concomitant nbDMARDs on persistence with the anti-TNF therapy has not been studied to our knowledge. In our study, there was a significant association between nbDMARD adherence and anti-TNF discontinuation in the period after the first 90 days. During that time period, compared with the most adherent patients ([80%), anti-TNF persistence worsened as nbDMARD adherence decreased. It is likely that the lack of an association in the first 90 days after starting the anti-TNF reflected discontinuations due to primary non-response to the anti-TNF therapy, which is typically considered to be in the first 12 weeks [30]. One hypothesis is that after the first 90 days, the difference in persistence may be linked to differences in the maintenance of response achieved by those on combination therapy. MTX co-administration may increase the bioavailability of anti-TNF therapies and reduce the development of anti-drug antibodies, thus prolonging the therapeutic effect of the anti-TNF [31]. Those with concomitant therapy with an nbDMARD typically have lower rates of discontinuation due to adverse events [8, 26, 28] . One hypothesis offered to explain this is that nbDMARDs (MTX specifically) may help reduce or prevent human anti-chimeric antibodies known to be induced by anti-TNFs [8, 26, 32 ]. This has not been formally tested, and the literature posing this hypothesis acknowledges possible confounding due to unmeasured patient characteristics, such as the ability to tolerate, and the possibility of partially responding to, treatment with nbDMARDs. Although most physicians believe their patients are compliant with combination therapy, our review of claims data demonstrate that this is not occurring in the majority of patients. Given that there are 53% to 59% of No consensus exists regarding the level of medication adherence that is considered optimal for patients with RA in a real-world setting, although a systematic review from 2010 concluded that ''most studies show that adherence is inadequate in many patients'' 
CONCLUSIONS
In conclusion, our results are consistent with other studies in that we found that almost one-third of patients with RA receiving anti-TNF therapy received it as pure monotherapy. Furthermore, one-third of those receiving any combination therapy (anti-TNF ? nbDMARDs) had \60% adherence to nbDMARDs. Physicians should take this into consideration when prescribing combination therapy and may want to consider prescribing a biologic that is known to be efficacious when used as a monotherapy or combination with nbDMARDs. We also found that lack of adherence with nbDMARDs resulted in poorer anti-TNF persistence in the period [90 days after starting the anti-TNF therapy, suggesting that concomitant nbDMARD use may play a role in maintenance of response to anti-TNF therapy. Further research is warranted to assess the reasons for, and effects of, the observed lower adherence to concomitant nbDMARDs on clinical outcomes.
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